Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · compa
The model's full reasoning — Q4 2017 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use transcript. Gate 1: positive current development with Q&A adding more concrete operating detail than prepared remarks. Need identify. Prepared remarks: 8-inch demand robust, 28nm recovery, HPC plus, 22nm, CapEx ROI, etc. Q&A: Analysts probe 28nm outlook, 8-inch strength, Europe/Japan growth, etc. Management adds specifics: 28nm tape-outs expected double, HPC plus on track, 22nm release end of year, 8-inch demand from RF switch, MCU, display driver, AMOLED, etc. Also 12X China capacity plans: 17k midyear, 22k end year. But is that positive current? Yes. Q&A adds details about 8-inch applications, 28nm tape-outs, China fab capacity. Multiple exchanges. However need check if "current" development: 8-inch robust demand, 28nm recovery with tape-outs. Management gives specifics. Gate 1 likely YES. Gate 2: Improvement filter. Main positive development: 8-inch demand robust, 28nm recovery. Is engine company-created or external? 8-inch demand driven by industry demand, "demand overwhelming", "robust" across applications. Management says "strong demand in 8-inch for 2018" from various applications. That's external market demand, not company-created. 28nm recovery: company's own technology and customer engagements, tape-outs, but also market. The main positive development highlighted is 8-inch strength and 28nm recovery. 8-inch strength is external demand (RF switch, MCU, display). 28nm recovery is company's own product/technology but also market. Need decide primary engine. The question asks "main POSITIVE, CURRENT development that management highlights and analysts probe". Could be 8-inch demand robust, 28nm recovery. 8-inch demand is external. 28nm recovery is company's own execution but also market. However management says "we are continuing our effort to capture new 28-nanometer business by working to secure new design opportunities" - that's company-created. But also "pricing pressure", "China players aggressive". The development is recovery through new tape-outs, HPC plus, 22nm. That is company's own technology roadmap and customer engagements. But is it "chiefly something the company itself created and controls"? Yes, they are developing technology, securing designs. However the demand for 8-inch is external. Which is main? Prepared remarks emphasize 8-inch robust demand and 28nm recovery.
The model's full reasoning — Q1 2018 call → NOWe need to evaluate both gates based on the transcript. Gate 1: Is there a positive, current development that management presents as going well, and does the Q&A produce more concrete operating detail than the prepared remarks? The prepared remarks mention: Q1 results, 8-inch and mature 12-inch stable loading, 94% utilization, Q2 guidance of wafer shipment increase 2-4%, ASP flat, gross margin mid-teens, capacity utilization mid-90s. They mention 28nm trough, but expect pickup. They mention 8-inch tight utilization, raw material cost increases, pricing adjustments. They also mention Xiamen fab expansion. In Q&A, analysts ask about 8-inch and mature nodes, pricing, capacity. Management says they haven't increased pricing due to demand, but adjusted for raw material costs. They focus on product mix improvement. They mention 8-inch has very little room for capacity increase, some CapEx allocated but not in 2018. For 12-inch, they are doing node-to-node changes. Analysts ask about 28nm rebound. Management says Q1 28nm was 12% of revenue, Q2 will pick up, poly-SiON solid, High-K more challenging, new customer base fragmented, tape outs in second half. They give some detail but not much new beyond prepared remarks. Analysts ask about 22nm schedule, management says on track for customer tape out first half of '19. Analysts ask about gross margin improvement, management attributes to more working days and improved 28nm loading. Analysts ask about 8-inch opportunities, management says they are focusing on long-term partnerships, product mix improvement, some CapEx for 8-inch. Analysts ask about RF SOI, management says they have success in 8-inch, expanding to 12-inch, but ecosystem not ready. Analysts ask about 28nm competition from China, management says they will remain competitive. Analysts ask about Xiamen fab, management says it's loss-making, drag on gross margin by 4-5%, will take time to reach economy of scale. Analysts ask about depreciation, tax credit, etc. So what is the positive current development? Possibly the 8-inch and mature node strength, with high utilization. But management says they haven't increased pricing, they are just managing mix. The Q&A doesn't seem to add much concrete detail beyond what was in prepared remarks. For example, on 8-inch, they say "very little room" for capacity, but that's not new.
The model's full reasoning — Q3 2016 call → NOThe transcript shows UMC's Q3 2016 earnings call. Let me evaluate both gates. Gate 1: Is there a positive, current development that management presents as genuinely going well, and does the Q&A produce more concrete operating detail than the prepared remarks? The prepared remarks mention: - 28nm business exceeded 20% of quarterly revenue for the first time - Fab 12X in Xiamen entering production for 40/55nm - 8-inch fabs fully loaded in Q4 In the Q&A, analysts probe several areas: - 8-inch loading: management says 8-inch is fully loaded in Q4, driven by large panel driver ICs. This is somewhat additive. - 28nm mix: management provides details on High-K/Metal Gate vs poly-SiON mix (70% HKMG capacity, 30% poly-SiON; shipments 63% poly-SiON, 37% HKMG). This is new detail. - Xiamen Fab: management says initial production will be in communication and consumer segments, focusing on AP, baseband, Wi-Fi, audio codec. This is somewhat additive. - 14nm: management says on track, first customer tap-out this quarter, wafer start early next year. The Q&A does add some specifics about 28nm mix, 8-inch drivers, and Xiamen customer segments. However, much of the Q&A is about guidance, margins, depreciation, and housekeeping. The positive developments (28nm growth, 8-inch recovery) do get some additional detail in Q&A - for example, the 28nm HKMG vs poly-SiON split, and the 8-inch being driven by large panel driver ICs. Is this "substantive" enough? The 28nm mix detail is new and specific. The 8-inch driver identification is new. The Xiamen segment focus is new. These are multiple exchanges with some additive detail. However, I need to consider whether the detail is truly substantive about actual operations. The 28nm mix percentages are concrete. The 8-inch driver (large panel driver ICs) is concrete. The Xiamen focus areas are concrete. I'd say Gate 1 is arguably YES - there is a positive current development (28nm growth, 8-inch recovery) and the Q&A does add some concrete operating detail beyond the prepared remarks. Gate 2: Is the development chiefly something the company itself created and controls, or is it riding an external environment? The 28nm growth is driven by "strong chip demand within the communications segment" - this is end-market demand. The 8-inch recovery is driven by "large panel driver" demand - also end-market.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNDY | monday.com Ltd. | Q4 2024 | 2024-05-15 | A |
| ZLAB | Zai Lab Limited | Q1 2024 | 2024-05-09 | B |
| YOU | Clear Secure, Inc. | Q1 2024 | 2024-05-08 | C+ |
| STIM | Neuronetics, Inc. | Q1 2024 | 2024-05-07 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q1 2024 | 2024-04-24 | A |
| CSGP | CoStar Group, Inc. | Q1 2024 | 2024-04-23 | B+ |
| SAP | SAP SE | Q1 2024 | 2024-04-22 | B |
| AREC | American Resources Corporation | Q4 2023 | 2024-03-28 | F |
| QRHC | Quest Resource Holding Corporation | Q4 2023 | 2024-03-12 | C+ |
| ALKT | Alkami Technology, Inc. | Q4 2023 | 2024-03-02 | A |
| MCW | Mister Car Wash, Inc. | Q4 2023 | 2024-02-21 | D |
| TYL | Tyler Technologies, Inc. | Q4 2023 | 2024-02-15 | C+ |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | B+ |
| SYY | Sysco Corporation | Q2 2024 | 2024-01-30 | B+ |
| STLD | Steel Dynamics, Inc. | Q4 2023 | 2024-01-24 | C+ |
| CSPI | CSP Inc. | Q4 2023 | 2023-12-12 | D |
| ATXS | Astria Therapeutics, Inc. | Q3 2023 | 2023-11-13 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| SG | Sweetgreen, Inc. | Q3 2023 | 2023-11-04 | D |
| CHRD | Chord Energy Corporation | Q3 2023 | 2023-11-02 | A |
| PLTR | Palantir Technologies Inc. | Q3 2023 | 2023-11-02 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GSK | GSK plc | Q3 2023 | 2023-11-01 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| DNUT | Krispy Kreme, Inc. | Q2 2023 | 2023-08-10 | C |
| RBLX | Roblox Corporation | Q2 2023 | 2023-08-09 | C+ |
| PODD | Insulet Corporation | Q2 2023 | 2023-08-08 | B+ |
| MVST | Microvast Holdings, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| CIVI | Civitas Resources, Inc. | Q2 2023 | 2023-08-03 | B |
| IDT | IDT Corporation | Q3 2023 | 2023-06-05 | C |
| STIM | Neuronetics, Inc. | Q1 2023 | 2023-05-13 | B |
| VECO | Veeco Instruments Inc. | Q1 2023 | 2023-05-08 | B |
| LTH | Life Time Group Holdings, Inc. | Q1 2023 | 2023-04-25 | A |
| SCPH | scPharmaceuticals Inc. | Q4 2022 | 2023-03-22 | C+ |
| COCO | The Vita Coco Company, Inc. | Q4 2022 | 2023-03-08 | B |
| PBPB | Potbelly Corporation | Q4 2022 | 2023-03-02 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| LANC | Lancaster Colony Corporation | Q2 2023 | 2023-02-02 | B+ |
| NVS | Novartis AG | Q4 2022 | 2023-02-01 | B |
| RELL | Richardson Electronics, Ltd. | Q2 2023 | 2023-01-05 | B+ |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| MUR | Murphy Oil Corporation | Q3 2022 | 2022-11-03 | B+ |
| LPX | Louisiana-Pacific Corporation | Q3 2022 | 2022-11-01 | B+ |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | B+ |
| INVZ | Innoviz Technologies Ltd | Q2 2022 | 2022-08-10 | D |
| FLGT | Fulgent Genetics, Inc. | Q2 2022 | 2022-08-04 | C+ |
| GTHX | G1 Therapeutics, Inc. | Q1 2022 | 2022-08-03 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| TMUS | T-Mobile US, Inc. | Q2 2022 | 2022-07-27 | B+ |
| AZO | AutoZone, Inc. | Q3 2022 | 2022-05-24 | B+ |
| AXON | Axon Enterprise, Inc. | Q1 2022 | 2022-05-10 | B+ |
| VEV | Vicinity Motor Corp. | Q4 2021 | 2022-03-30 | D |
| HRTX | Heron Therapeutics, Inc. | Q4 2021 | 2022-02-28 | D |
| INCY | Incyte Corporation | Q4 2021 | 2022-02-08 | C+ |
| TMDX | TransMedics Group, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ATRC | AtriCure, Inc. | Q3 2021 | 2021-11-03 | C |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2021 | 2021-11-03 | C+ |
| ZI | ZoomInfo Technologies Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CHWY | Chewy, Inc. | Q2 2021 | 2021-09-01 | B |
| VVV | Valvoline Inc. | Q3 2021 | 2021-08-06 | B+ |
| TIGO | Millicom International Cellular S.A. | Q2 2021 | 2021-07-31 | B+ |
| SAP | SAP SE | Q2 2021 | 2021-07-21 | B+ |
| UPWK | Upwork Inc. | Q3 2018 | 2018-11-11 | B+ |
| MYO | Myomo, Inc. | Q3 2018 | 2018-11-05 | C |
| CFG | Citizens Financial Group, Inc. | Q3 2018 | 2018-10-19 | A |
| UAL | United Airlines Holdings, Inc. | Q3 2018 | 2018-10-17 | B+ |
| INSP | Inspire Medical Systems, Inc. | Q2 2018 | 2018-08-12 | A |
| REI | Ring Energy, Inc. | Q2 2018 | 2018-08-09 | B |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | B+ |
| RNG | RingCentral, Inc. | Q2 2018 | 2018-08-06 | A |
| FRPT | Freshpet, Inc. | Q2 2018 | 2018-08-06 | B+ |
| TSLA | Tesla, Inc. | Q2 2018 | 2018-08-02 | B |
| OOMA | Ooma, Inc. | Q1 2019 | 2018-05-22 | A |
| ZG | Zillow Group's | Q1 2018 | 2018-05-08 | C+ |
| QLYS | Qualys, Inc. | Q1 2018 | 2018-05-02 | B+ |
| CPS | Cooper-Standard Holdings Inc. | Q1 2018 | 2018-05-02 | B |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SYK | Stryker Corporation | Q1 2018 | 2018-04-26 | B+ |
| TNC | Tennant Company | Q4 2017 | 2018-02-22 | B |
| TMUS | T-Mobile US, Inc. | Q4 2017 | 2018-02-09 | B+ |
| NICE | NICE Ltd. | Q3 2017 | 2017-11-04 | A |
| SAMG | Silvercrest Asset Management Group Inc. | Q3 2017 | 2017-11-03 | A |
| VC | Visteon Corporation | Q3 2017 | 2017-10-28 | B+ |
| PRO | PROS Holdings, Inc. | Q3 2017 | 2017-10-26 | B+ |
| SRPT | Sarepta Therapeutics, Inc. | Q3 2017 | 2017-10-26 | C+ |
| CAL | Caleres, Inc. | Q2 2017 | 2017-08-29 | B+ |
| LITE | Lumentum Holdings Inc. | Q4 2017 | 2017-08-09 | B+ |
| FRPT | Freshpet, Inc. | Q2 2017 | 2017-08-07 | B+ |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | B+ |
| ADAP | Adaptimmune Therapeutics plc | Q1 2017 | 2017-05-10 | D |
| ISDR | Issuer Direct Corporation | Q1 2017 | 2017-05-06 | C |
| XPO | XPO Logistics, Inc. | Q1 2017 | 2017-05-04 | B |
| SRPT | Sarepta Therapeutics, Inc. | Q1 2017 | 2017-04-28 | D |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| SYK | Stryker Corporation | Q4 2016 | 2017-01-24 | C+ |
| MCS | The Marcus Corporation | Q3 2016 | 2016-10-27 | C+ |
| GSK | GSK plc | Q3 2016 | 2016-10-26 | B |
| VYGR | Voyager Therapeutics, Inc. | Q2 2016 | 2016-08-11 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| DGII | Digi International Inc. | Q3 2016 | 2016-07-28 | B |
| PAR | PAR Technology Corporation | Q1 2016 | 2016-05-04 | D |
| PM | Philip Morris International Inc. | Q1 2016 | 2016-04-19 | B+ |
RBLX · Q2 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in advertising, where management's prepared remarks mention live ads, 200 activations, 19% of top 100 with ad units, and some demand exceeding supply. In the Q&A, they add fresh specifics like pricing strategy (gentle now, floating later), new ad unit types, 12% of top 100 using portals, demand in 17-24 female cohort, self-serve options, and brand volume challenges. These details are operational and additive across multiple exchanges, meeting GATE 1 criteria. For GATE 2, advertising is driven by Roblox's own creation and control: 200 activations, portal ad units, self-serve platform, and rollout execution. It's not reliant on external industry tailwinds but on their platform improvements and brand engagement. This satisfies the primary engine condition.
SG · Q3 2023 → YESThe task is to evaluate two gates based on the Sweetgreen earnings call transcript and return YES only if both gates are YES, otherwise NO. YES The transcript shows a clear positive current development in Infinite Kitchen, with management's Q&A responses adding substantial new operational details—such as first-unit performance, customer experience improvements, margin leverage, AUV targeting, retrofit opportunities, and throughput optimizations—that go beyond the prepared remarks' high-level plans. This satisfies Gate 1 criteria for additive, substantive detail across multiple exchanges. For Gate 2, Infinite Kitchen is a proprietary technology the company developed and controls, with momentum driven by its own execution, customer adoption, and operational refinements rather than external tailwinds, making it the primary engine.
ALKT · Q4 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in the bank's market progress and add-on sales momentum, with Q&A providing substantial new operational details like specific backlog numbers, implementation timelines, product adoption rates, and customer-specific challenges that go beyond the prepared remarks. For GATE 2, the primary engine is Alkami's own platform, cloud-native architecture, and execution on replacements of legacy systems, which would largely continue even if external conditions shifted, as the company is actively winning share through its controlled rollout and product improvements.